Intangible Assets - License Agreements (Details) - USD ($) |
3 Months Ended | |
|---|---|---|
Mar. 31, 2020 |
Mar. 31, 2019 |
|
| Sales and Marketing Expense | ||
| Intangible assets | ||
| Royalty fees included in sales and marketing expense | $ 492,000 | $ 449,000 |
| License Agreements | ||
| Intangible assets | ||
| Notice period for termination of license agreements | 60 days | |
| Minimum royalty of agreements | $ 12,500 | |
| Milestone fee upon receiving a Phase II Small Business Innovation Research | 15,000 | |
| Milestone fee upon FDA approval | 125,000 | |
| Milestone fee upon first commercial use of certain licensed technology | 25,000 | |
| Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products | $ 10,000 | |
| License Agreements | Minimum | ||
| Intangible assets | ||
| Royalty fees range under the license agreements | 1.00% | |
| License Agreements | Maximum | ||
| Intangible assets | ||
| Royalty fees range under the license agreements | 3.00% | |
| Royalty stack cap for royalties paid to more than one licensor for sales of the same product | 3.75% | |
| X | ||||||||||
- Definition Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance Nerve Graft. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement. No definition available.
|
| X | ||||||||||
- Definition Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements. No definition available.
|
| X | ||||||||||
- Definition Notice period for termination of license agreements. No definition available.
|
| X | ||||||||||
- Definition The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements. No definition available.
|
| X | ||||||||||
- Definition Royalty fees percentage under license agreements. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|